                         SEQUENCE LISTING

<110>  HUMANIGEN, INC.
 
<120>  METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF
        ANTAGONIST

<130>  P-566450-PC11

<140>  PCT/US18/053933
<141>  2018-10-02

<150>  US 62/729,043
<151>  2018-09-10

<150>  US 62/567,187
<151>  2017-10-02

<160>  39    

<170>  PatentIn version 3.5

<210>  1
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-granulocyte-macrophage

       colony-stimulating factor (GM-CSF) antibody heavy

       chain variable region (VH) VH#1

<400>  1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Val Arg Arg Asp Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  2
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-granulocyte-macrophage

       colony-stimulating factor (GM-CSF) antibody heavy

       chain variable region (VH) VH#2

<400>  2

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asn Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Ala Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Asp Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  3
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-granulocyte-macrophage

       colony-stimulating factor (GM-CSF) antibody heavy

       chain variable region (VH) VH#3

<400>  3

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asn Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Ala Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gln Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  4
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-granulocyte-macrophage

       colony-stimulating factor (GM-CSF) antibody heavy

       chain variable region (VH) VH#4

<400>  4

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asn Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Ala Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Val Arg Arg Gln Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  5
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-granulocyte-macrophage

       colony-stimulating factor (GM-CSF) antibody heavy

       chain variable region (VH) VH#5

<400>  5

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asn Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Val Arg Arg Gln Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  6
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-granulocyte-macrophage

       colony-stimulating factor (GM-CSF) antibody kappa

       light chain variable region (VL) VK#1

<400>  6

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Val Leu Ile 
        35                  40                  45              


Tyr Ser Thr Ser Ser Arg Ala Thr Gly Ile Thr Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Asn Arg Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  7
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-granulocyte-macrophage

       colony-stimulating factor (GM-CSF) antibody kappa

       light chain variable region (VL) VK#2

<400>  7

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Val Leu Ile 
        35                  40                  45              


Tyr Ser Thr Ser Ser Arg Ala Thr Gly Ile Thr Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Asn Lys Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  8
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-granulocyte-macrophage

       colony-stimulating factor (GM-CSF) antibody kappa

       light chain variable region (VL) VK#3

<400>  8

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Ser Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Val Leu Ile 
        35                  40                  45              


Tyr Ser Thr Ser Ser Arg Ala Thr Gly Ile Thr Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Asn Arg Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  9
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic anti-granulocyte-macrophage

       colony-stimulating factor (GM-CSF) antibody kappa

       light chain variable region (VL) VK#4

<400>  9

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Ser Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Val Leu Ile 
        35                  40                  45              


Tyr Ser Thr Ser Ser Arg Ala Thr Gly Ile Thr Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Asn Lys Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  10
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic kappa constant region

<400>  10

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
1               5                   10                  15      


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
            20                  25                  30          


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
        35                  40                  45              


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
65                  70                  75                  80  


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
                85                  90                  95      


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            100                 105         


<210>  11
<211>  330
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic f-allotype heavy chain constant region

<400>  11

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 
225                 230                 235                 240 


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  12
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 3 (CDR3)

       binding specificity determinant (BSD)

<400>  12

Arg Gln Arg Phe Pro Tyr 
1               5       


<210>  13
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 3 (CDR3)

       binding specificity determinant (BSD)

<400>  13

Arg Asp Arg Phe Pro Tyr 
1               5       


<210>  14
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH) human

J-segment JH4

<400>  14

Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10                  15  


<210>  15
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 3 (CDR3)

<400>  15

Arg Gln Arg Phe Pro Tyr Tyr Phe Asp Tyr 
1               5                   10  


<210>  16
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 3 (CDR3)

<400>  16

Arg Asp Arg Phe Pro Tyr Tyr Phe Asp Tyr 
1               5                   10  


<210>  17
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL)

       complementarity-determining region 3 (CDR3)


<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa = Lys or Arg

<400>  17

Gln Gln Phe Asn Xaa Ser Pro Leu Thr 
1               5                   


<210>  18
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL)

       complementarity-determining region 3 (CDR3)

<400>  18

Gln Gln Phe Asn Lys Ser Pro Leu Thr 
1               5                   


<210>  19
<211>  96
<212>  PRT
<213>  Homo sapiens

<400>  19

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ala Tyr Met Glu 
65                  70                  75                  80  


Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
                85                  90                  95      


<210>  20
<211>  97
<212>  PRT
<213>  Homo sapiens

<400>  20

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Gly 
        35                  40                  45              


Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe Gln 
    50                  55                  60                  


Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met 
65                  70                  75                  80  


Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg 
    


<210>  21
<211>  96
<212>  PRT
<213>  Homo sapiens

<400>  21

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
                85                  90                  95      


<210>  22
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 3 (CDR3)


<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa = Gln or Asp

<400>  22

Arg Xaa Arg Phe Pro Tyr 
1               5       


<210>  23
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic combination of heavy chain variable

       region (VH) complementarity-determining region 3

       (CDR3) binding specificity determinant (BSD) and

       human germline J-segment JH4 (CDRH3 and FR4)


<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa = Gln or Asp

<400>  23

Arg Xaa Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
1               5                   10                  15      


Val Thr Val Ser Ser 
            20      


<210>  24
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 1 (CDR1)

<400>  24

Gly Tyr Tyr Met His 
1               5   


<210>  25
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 1 (CDR1)

<400>  25

Asn Tyr Tyr Ile His 
1               5   


<210>  26
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 2 (CDR2)

<400>  26

Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  27
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 2 (CDR2)

<400>  27

Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL)

       complementarity-determining region 3 (CDR3)

<400>  28

Gln Gln Phe Asn Arg Ser Pro Leu Thr 
1               5                   


<210>  29
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic combination of light chain variable

       region (VL) complementarity-determining region 3

       (CDR3) binding specificity determinant (BSD) and

       human germline J-segment JK4 (CDRL3 and FR4)

<400>  29

Gln Gln Phe Asn Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 
1               5                   10                  15      


Glu Ile Lys 
            


<210>  30
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic combination of light chain variable

       region (VL) complementarity-determining region 3

       (CDR3) binding specificity determinant (BSD) and

       human germline J-segment JK4 (CDRL3 and FR4)

<400>  30

Gln Gln Phe Asn Lys Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 
1               5                   10                  15      


Glu Ile Lys 
            


<210>  31
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL)

       complementarity-determining region 1 (CDR1)

<400>  31

Arg Ala Ser Gln Ser Val Gly Thr Asn Val Ala 
1               5                   10      


<210>  32
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL)

       complementarity-determining region 1 (CDR1)

<400>  32

Arg Ala Ser Gln Ser Ile Gly Ser Asn Leu Ala 
1               5                   10      


<210>  33
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL)

       complementarity-determining region 2 (CDR2)

<400>  33

Ser Thr Ser Ser Arg Ala Thr 
1               5           


<210>  34
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL) FR4

region

<400>  34

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
1               5                   10  


<210>  35
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 1 (CDRH1)

<400>  35

Asp Tyr Asn Ile His 
1               5   


<210>  36
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic heavy chain variable region (VH)

       complementarity-determining region 2 (CDRH2)

<400>  36

Tyr Ile Ala Pro Tyr Ser Gly Gly Thr Gly Tyr Asn Gln Glu Phe Lys 
1               5                   10                  15      


Asn 
    


<210>  37
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL)

       complementarity-determining region 1 (CDRL1)

<400>  37

Lys Ala Ser Gln Asn Val Gly Ser Asn Val Ala 
1               5                   10      


<210>  38
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL)

       complementarity-determining region 2 (CDRL2)

<400>  38

Ser Ala Ser Tyr Arg Ser Gly 
1               5           


<210>  39
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic light chain variable region (VL)

       complementarity-determining region 1 (CDR1)


<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa = Val or Ile

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa = Thr or Ser

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  Xaa = Val or Leu

<400>  39

Arg Ala Ser Gln Ser Xaa Gly Xaa Asn Xaa 
1               5                   10  


